about
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyCancer immunotherapy: the beginning of the end of cancer?Current and future molecular profiling of cancer by next-generation sequencingThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsNivolumab in the treatment of malignant melanoma: review of the literatureThe past, present and future of immunotherapy against tumorImmunotherapy for prostate cancer: recent developments and future challengesEtiologic field effect: reappraisal of the field effect concept in cancer predisposition and progressionThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentCurrent systemic treatment of hepatocellular carcinoma: A review of the literatureSafety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesImmune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacyPromising targets and current clinical trials in metastatic squamous cell lung cancerStructural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Vα CDR3Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progressionT cell costimulatory and coinhibitory pathways in vascular inflammatory diseasesCancer immunotherapy via dendritic cellsSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeTumor microenvironment complexity: emerging roles in cancer therapy.Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes.Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Immunocompetent murine models for the study of glioblastoma immunotherapyThe translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous MelanomaTargeting the PD-1 pathway: a promising future for the treatment of melanoma.VISTA Regulates the Development of Protective Antitumor Immunity.The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients.PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancerAwareness and understanding of cancer immunotherapy in Europe.Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma.Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.Targeting the tumor microenvironment to enhance antitumor immune responses
P2860
Q24633070-D9589DE2-84B5-48A8-90FC-1BEAA14B5F79Q26745516-ADAD2CD4-7DB3-47CC-831A-B698571F19FCQ26752277-B3F6FE79-96BC-4875-A46D-B0E9F9F7BD6BQ26796272-B0E8BB8E-A4D2-4BDB-A53C-4BA2BF91F8ECQ26797478-5F48FA91-CD3D-4962-A77D-49D139AAC1F4Q26798330-0A06C7B2-6FFB-4807-92C3-873B07EDA8CAQ26799896-D603F53C-BB98-4EE8-9B12-2E50C6D5500CQ26852388-2DAB10DB-3A30-499F-A4C8-F41FA835851DQ26852716-5A4EC0F3-2C07-4389-A8B2-65099C7A9163Q27022789-34C16CA9-D130-45EF-95FA-EC3694E00720Q27026036-36912234-2E23-444D-BD51-D86658FC0DFBQ27860857-25DEED1D-C3EF-4456-95EA-985D9D67AA6AQ28074619-9A5089FA-3ED2-49D9-A20F-7B8FD31455FCQ28082914-18FD543A-6881-4D66-9A4D-EA34A545D7B7Q28083663-FB5370C0-32F3-44F7-9CF3-4F0503AC9605Q28273830-4D7F1BAC-DC17-4FBE-A05B-A815C93A5527Q28304978-3F4E8EFF-DF42-49D1-94ED-9FCB8A80181CQ28396774-B3B2CD50-7EAF-4068-AE1D-6F99CFBAAD17Q29615444-8D66360E-D2CF-4736-8D3E-EEE2E1A50EFAQ29620596-7DB51B6D-57D6-46C6-9A87-2BA408310C44Q29620881-F0455377-BB9D-4853-BDC2-4FD685E0E090Q30419311-2D46B7D9-70E9-4BE0-A193-C06BC74D65D1Q30558949-A42D91C3-4C91-4CAB-A990-B45CA01FF58BQ30916013-6CB23FCC-BCD6-4AAD-94CA-56227EAC0850Q33574853-573D5C02-6BA5-4932-B7A9-B3985EC575F5Q33636990-7E45D72D-F847-4B92-8BD1-4B6C3B7F242DQ33741471-43D876E2-A867-4A17-966D-A115788A13E9Q33946513-342F29DE-6F0A-420A-B384-214C8825FE7FQ33978040-692A2C0C-4549-4572-8254-6E2177A17CF7Q34068134-599BD206-D4B1-4C68-8DFF-CAD058158D4BQ34265875-EB611044-8E16-42B7-A798-FCCDEDF2D236Q34291043-F9399145-29B5-4B98-83DB-E8C53B4B2EF8Q34292741-C38EA452-A285-4D14-A15F-F8B4D2C13834Q34391263-AC5AB25D-A9F3-48BC-B1BB-FDD291AC2163Q34661815-51FC9400-7873-4EB9-80F0-71F91ED8092DQ34717034-C6ED5747-A2E5-4409-A1CB-DDB60D9222B1Q34859794-99201EA7-9A88-4205-BB70-8E58E2C45D02Q34871657-803C5489-343A-4B64-B866-A2C179696FFAQ35085309-A4965D10-1B09-4E5D-AF9E-0418F6806AE3Q35176307-3657CB81-C4C9-47BE-B68E-8750575383D2
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cancer immunotherapy comes of age
@ast
Cancer immunotherapy comes of age
@en
type
label
Cancer immunotherapy comes of age
@ast
Cancer immunotherapy comes of age
@en
prefLabel
Cancer immunotherapy comes of age
@ast
Cancer immunotherapy comes of age
@en
P2093
P2860
P356
P1476
Cancer immunotherapy comes of age
@en
P2093
Drew M Pardoll
George J Weiner
Suzanne L Topalian
P2860
P304
P356
10.1200/JCO.2011.38.0899
P407
P577
2011-10-31T00:00:00Z